Hodgkin lymphoma with hypereosinophilia in a pediatric patient: case report and review of the literature
By
Rosa Margarita Cruz Osorio
Regina M. Navarro-Martin del Campo
Wangky Carolina Carrasco-Rivera
Lisette Paola Bruijnzeels-Ponce
Jesús Alejandro Gutiérrez-Ortiz
Hannali Quintero-Buenrostro
Violeta Salceda-Rivera
Manuel Donovan Martinez-Albarran
Diego Ugalde-Aviña
Veronica Soto Chavez
Fernando Sánchez-Zubieta
Oscar Gonzalez-Ramella
May 20, 2026
Clinical Scorecard: Pediatric Hodgkin Lymphoma Associated with Hypereosinophilia: A Case Study and Literature Review
At a Glance
Category Detail
Condition Key Mechanisms Characterized by Reed-Sternberg cells; hypereosinophilia (>1,500/µL) may result from cytokines produced by malignant cells. Target Population Care Setting
Key Highlights
HL comprises 6% of pediatric cancers, with a bimodal incidence. Hypereosinophilia occurs in 15% of HL cases, with extreme levels (>1.5 × 10⁹/L) being rare. Nodular sclerosis classical Hodgkin lymphoma (NS-cHL) is the most prevalent subtype. The case highlights the diagnostic challenges posed by atypical presentations. Successful treatment involved chemotherapy (OEPA/COPDAC) followed by radiotherapy. Guideline-Based Recommendations
Diagnosis
Consider HL in patients with unexplained hypereosinophilia. Utilize lymph node biopsy for definitive diagnosis. Management
Initiate treatment with OEPA/COPDAC regimen. Consider radiotherapy for incomplete metabolic response. Monitoring & Follow-up
Regular follow-up with PET-CT to assess treatment response. Monitor eosinophil counts during and after therapy. Risks
Potential for misdiagnosis due to atypical presentations. Risk of treatment-related complications. Patient & Prescribing Data
Eosinophil counts declined significantly post-therapy, indicating treatment efficacy.
Clinical Best Practices
Maintain a high index of suspicion for HL in cases of severe eosinophilia. Conduct thorough diagnostic evaluations to rule out secondary causes of eosinophilia. Related Resources & Content
